Atanasio
Pandiella Alonso
Universidad de Cantabria
Santander, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Cantabria (7)
2022
-
Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma
Biomolecules, Vol. 12, Núm. 11
2021
2017
-
CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia
Oncotarget, Vol. 8, Núm. 18, pp. 29679-29698
-
ODZ1 allows glioblastoma to sustain invasiveness through a Myc-dependent transcriptional upregulation of RhoA
Oncogene, Vol. 36, Núm. 12, pp. 1733-1744
2013
-
Cellular plasticity confers migratory and invasive advantages to a population of glioblastoma-initiating cells that infiltrate peritumoral tissue
Stem Cells, Vol. 31, Núm. 6, pp. 1075-1085
2002
-
Mitogen-activated protein kinase routes as targets in the action of Diaza-anthracene compounds with a potent growth-inhibitory effect on cancer cells
Molecular Cancer Therapeutics, Vol. 1, Núm. 10, pp. 811-819